ADARx Pharmaceuticals, Inc. $ADRX
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING6
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO100%
Delay Index: of 5 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +29.9 months). See all sponsors →
Open ADARx Pharmaceuticals, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| STOP-HAE NCT06960213 |
P3 | Recruiting | Hereditary Angioedema; HAE | 90 | 2027-11-30 (+11 mo) |
| ADX-324 NCT05691361 |
P1/2 | Active, not recruiting | Hereditary Angioedema | 53 | 2027-12-31 (+48 mo) |
| PNH NCT05876312 |
P1/2 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 50 | 2028-03-31 (+40 mo) |
| ADX-038 NCT07522099 |
P2 | Recruiting | Immunoglobulin A Nephropathy (IgAN); Complement 3 Glomerulopathy (C3G) | 30 | 2028-07-10 |
| ADX-038 Dose Level 2 NCT06989359 |
P2 | Recruiting | IgAN; C3G | 45 | 2028-12-31 (+18 mo) |
| ADX-038 NCT06990269 |
P2 | Recruiting | Geographic Atrophy Secondary to Age-related Macular Degeneration | 240 | 2030-02-28 (+30 mo) |
| ADX-324 Dose Level 1 NCT07428499 |
P3 | Recruiting | Hereditary Angioedema (HAE); Hereditary Angioedema - Type 1 | 90 | 2030-06-30 |